Gilead Sciences
Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About GILD
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
GILD Key Statistics
Stock Snapshot
Gilead Sciences(GILD) stock is priced at $126.64, giving the company a market capitalization of 157.23B. It carries a P/E multiple of 19.36 and pays a dividend yield of 2.5%.
During the trading session on 2025-11-22, Gilead Sciences(GILD) shares reached a daily high of $127.98 and a low of $125.07. At a current price of $126.64, the stock is +1.3% higher than the low and still -1.0% under the high.
Trading activity shows a volume of 10.38M, compared to an average daily volume of 7.68M.
The stock's 52-week range extends from a low of $88.57 to a high of $128.70.
The stock's 52-week range extends from a low of $88.57 to a high of $128.70.
GILD News
Gilead Sciences recently announced the first shipments of its twice-yearly injectable HIV prevention medicine, lenacapavir, to Eswatini and Zambia, while also s...
Gilead Sciences (GILD) shares have edged higher recently, with the stock showing a steady climb over the past month. Investors are watching how recent performan...
Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions AI Analyst can help you make smarter investment...
Analyst ratings
71%
of 31 ratingsMore GILD News
Gilead (GILD) announced the delivery of first shipments of lenacapavir – Gilead’s twice-yearly injectable HIV-1 capsid inhibitor – for the prevention of HIV as...